SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-000683
Filing Date
2024-01-02
Accepted
2024-01-02 16:05:56
Documents
13
Period of Report
2024-01-02
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d582286d8k.htm   iXBRL 8-K 31235
2 EX-3.1 d582286dex31.htm EX-3.1 191184
  Complete submission text file 0001193125-24-000683.txt   385957

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mcrb-20240102.xsd EX-101.SCH 2868
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mcrb-20240102_lab.xml EX-101.LAB 17980
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mcrb-20240102_pre.xml EX-101.PRE 11270
7 EXTRACTED XBRL INSTANCE DOCUMENT d582286d8k_htm.xml XML 3447
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

IRS No.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37465 | Film No.: 24502399
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)